Evidence map›Paper›PMID 26334306›Full record

ArticlePLoS pathogens2015

Distinct but Spatially Overlapping Intestinal Niches for Vancomycin-Resistant Enterococcus faecium and Carbapenem-Resistant Klebsiella pneumoniae.

Silvia Caballero, Rebecca Carter, Xu Ke, Bože Sušac, Ingrid M Leiner, Grace J Kim, Liza Miller, Lilan Ling, Katia Manova, Eric G Pamer

Registry-linked trialOpen access · goldAbstract readComparative Study
In one paragraph

Article in PLoS pathogens, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06258551 (Dynamics of Colonization and Infection by Multidrug-Resistant Pathogens in Immunocompromised and Critically Ill Patients), which is not on this map. Cited by 77 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
77citing papers in PubMed, 1 pooled it
5.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06258551 unknown statusnot on this mapstarted 2020, after this paper: background citation

Dynamics of Colonization and Infection by Multidrug-Resistant Pathogens in Immunocompromised and Critically Ill Patients

TypeobservationalSponsorThe Methodist Hospital Research InstituteRan2020 to 2026Enrolled1,000ConditionsAntimicrobial Drug Resistance, Antibiotic Resistant Infection, Clostridium Difficile, Carbapenem-Resistant Enterobacteriaceae Infection
3 · Its place in the literature

Who cites it

77 citing papers in PubMed, 1 synthesis or guideline pooled it, 116 citations in OpenAlex.

  1. Pooled it
  2. Fecal Microbial Transplants Reduce Antibiotic-resistant Genes in Patients With Recurrent Clostridium difficile Infection.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2016
    Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. A Novel Technique to CharacterizebioRxiv : the preprint server for biology · 2025
    Article
  9. Sugar Import SuppressesbioRxiv : the preprint server for biology · 2025
    Article
  10. Article
  11. Article
  12. Article
  13. Host-pathobiont interactions in Crohn's disease.Nature reviews. Gastroenterology & hepatology · 2025
    Review
  14. Article
  15. Deciphering the gastrointestinal carriage ofInfection and immunity · 2024
    Review
  16. Review
  17. Review
  18. Plant-Origin Components: New Players to Combat Antibiotic Resistance inInternational journal of molecular sciences · 2024
    Review
  19. Article
  20. Review

17 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Silvia CaballeroImmunology Program and Infectious Disease Service, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America; Immunology and Microbial Pathogenesis Program, Weill Cornell Graduate School of Medical Sciences, New York, New York, United States of America.
Rebecca CarterImmunology Program and Infectious Disease Service, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America.
Xu KeMolecular Cytology Core Facility, Sloan-Kettering Institute, New York, New York, United States of America.
Bože SušacImmunology Program and Infectious Disease Service, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America.
Ingrid M LeinerImmunology Program and Infectious Disease Service, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America.
Grace J KimLucille Castori Center for Microbes, Inflammation and Cancer, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America.
Liza MillerLucille Castori Center for Microbes, Inflammation and Cancer, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America.
Lilan LingLucille Castori Center for Microbes, Inflammation and Cancer, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America.
Katia ManovaMolecular Cytology Core Facility, Sloan-Kettering Institute, New York, New York, United States of America.
Eric G PamerImmunology Program and Infectious Disease Service, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America; Immunology and Microbial Pathogenesis Program, Weill Cornell Graduate School of Medical Sciences, New York, New York, United States of America; Lucille Castori Center for Microbes, Inflammation and Cancer, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America.
Memorial Sloan Kettering Cancer Center · USKettering University · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Elisa de Stanchina · 1985 to 2026
$347.4M
TNF Mediated Immune Defense Against Listeria InfectionR01AI042135 · NIAID · YALE UNIVERSITY · PI PAMER, ERIC G. · 1998 to 2019
$7.3M
Innate Immune Defense against Clostridium Difficile InfectionR01AI095706 · NIAID · UNIVERSITY OF CHICAGO · PI PAMER, ERIC G. · 2012 to 2020
$3.4M
Howard Hughes Medical InstituteNCI NIH HHS P30 CA008748NIAID NIH HHS AI95706NIAID NIH HHS R01 AI042135NIAID NIH HHS R01 AI095706NIAID NIH HHS R01 AI42135
6 · The paper itself

Abstract

Antibiotic resistance among enterococci and γ-proteobacteria is an increasing problem in healthcare settings. Dense colonization of the gut by antibiotic-resistant bacteria facilitates their spread between patients and also leads to bloodstream and other systemic infections. Antibiotic-mediated destruction of the intestinal microbiota and consequent loss of colonization resistance are critical factors leading to persistence and spread of antibiotic-resistant bacteria. The mechanisms underlying microbiota-mediated colonization resistance remain incompletely defined and are likely distinct for different antibiotic-resistant bacterial species. It is unclear whether enterococci or γ-proteobacteria, upon expanding to high density in the gut, confer colonization resistance against competing bacterial species. Herein, we demonstrate that dense intestinal colonization with vancomycin-resistant Enterococcus faecium (VRE) does not reduce in vivo growth of carbapenem-resistant Klebsiella pneumoniae. Reciprocally, K. pneumoniae does not impair intestinal colonization by VRE. In contrast, transplantation of a diverse fecal microbiota eliminates both VRE and K. pneumoniae from the gut. Fluorescence in situ hybridization demonstrates that VRE and K. pneumoniae localize to the same regions in the colon but differ with respect to stimulation and invasion of the colonic mucus layer. While VRE and K. pneumoniae occupy the same three-dimensional space within the gut lumen, their independent growth and persistence in the gut suggests that they reside in distinct niches that satisfy their specific in vivo metabolic needs.

Indexed as

AmpicillinAnimalsAnti-Bacterial AgentsCarbapenemsColony Count, MicrobialDrug Resistance, BacterialEnteritisEnterococcus faeciumFecal Microbiota TransplantationFecesFemaleGastrointestinal MicrobiomeGram-Positive Bacterial InfectionsHost-Pathogen InteractionsIn Situ Hybridization, FluorescenceIntestinal MucosaAmpicillinAnti-Bacterial AgentsCarbapenems

Identifiers

PMID26334306
PMCPMC4559429
OpenAlexW1863177951

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.